 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | ZSP1603 / Guangdong Zhongsheng Pharma
Trial completion date, Trial primary completion date: Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis ?IPF? (clinicaltrials.gov) - Jul 18, 2023
P1/2, N=36, Recruiting, Sponsor: Guangdong Raynovent Biotech Co., Ltd
Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Oct 2022 --> Dec 2023
- || ZSP1603 / Guangdong Zhongsheng Pharma
New P1/2 trial: Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis ?IPF? (clinicaltrials.gov) - Nov 14, 2021
P1/2, N=36, Recruiting, Sponsor: Guangdong Raynovent Biotech Co., Ltd
- | ZSP1603 / Guangdong Zhongsheng Pharma
Preclinical, Journal: The antifibrotic effect and mechanism of a novel tyrosine kinase inhibitor, ZSP1603, in preclinical models of pulmonary fibrosis. (Pubmed Central) - Feb 12, 2021
Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Oct 2022 --> Dec 2023 ZSP1603 is an effective anti-fibrotic compound with clear mechanisms.
- | ZSP1603 / Guangdong Zhongsheng Pharma
Trial completion, Trial completion date: Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults (clinicaltrials.gov) - Oct 25, 2019
P1, N=40, Completed, Sponsor: Guangdong Zhongsheng Pharmaceutical Co., Ltd.
ZSP1603 is an effective anti-fibrotic compound with clear mechanisms. Recruiting --> Completed | Trial completion date: Jun 2019 --> Oct 2019
- | ZSP1603 / Guangdong Zhongsheng Pharma
New P1 trial: Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults (clinicaltrials.gov) - Aug 8, 2018
P1, N=32, Recruiting, Sponsor: Guangdong Zhongsheng Pharmaceutical Co., Ltd.